Use of MRD in Clinical Practice and Treatment Options for Mantle Cell Lymphoma

The chapter explores the use of minimal residual disease (MRD) in clinical practice and its impact on decision-making in treating mantle cell lymphoma. It also discusses the efficacy and safety of specific treatments, such as brutinib and CAR T-cell therapy, and highlights the importance of patient selection and individualized discussions for determining the most appropriate treatment approach.